Medicines for Smoking Cessation Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 – 2018 Smoking is the practice of inhaling or tasting of smoke released when a substance is burned. The most common substance used for smoking is tobacco while the cannabis and opium are also smoked often by people however less commonly. Most common smoking implement is cigarettes followed by pipes, bidis, hookahs, cigars and vaporizers. Smoking is considered as a serious threat to human health due to its risk associated with medical conditions such as heart diseases, pulmonary diseases, respiratory disorders, infertility, osteoporosis and cancer. Full Browse Report: http://www.transparencymarketresearch.com/medicinessmoking-cessation.html The primary cause for smoking is the gap between the lifestyles of different social classes. Curing of smoking related diseases is possible and because of intense health related concerns, primary health care providers are increasingly taking efforts for promoting cessation of smoking in patients. Prior to the initiation of smoking cessation therapy, important factors to be considered include patient’s willingness to opt for therapy, its medical history, previous experience with antismoking aids, and other patient characteristics such as contraindications, depression history and level of smoking. It is often recommended that pharmacologic therapy should be combined with appropriate behavioral counseling to the patient in order to enhance cessation rates in long term. Common antismoking aids include prescription drugs, over-the-counter products, nicotine replacement therapy, nicotine receptor partial agonist and antidepressant therapy along with counseling, encouragement and support or referral to quit smoking and programs for the same. Drugs for smoking cessation are categorized as first line agents, second line agents and combination therapy. Several first line medications have been already approved by the FDA for individuals attempting to quit smoking while there are several other therapies which are recommended only if the patient is unable to quit smoking with mono-therapy. Currently, the number of prescriptions for nicotine replacement therapy and bupropion has been seen to reduce with a simultaneous increase in the number of prescriptions for varenicline. The major reason for growth in the scope of this market is the increased number of smokers willing to curb smoking habit. The market is predicted to grow continuously due to the rising incidence and prevalence of smoking in developed and under-developed countries. Various innovations and formulations in pipeline
Medicines for smoking cessation market global industry analysis, size, share, growth, trends 2018
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.